美国FDA生物制品紫皮书数据库
(U.S. FDA Purple Book: Database of Licensed Biological Products)
商品名 申请号 产品号 BLA类型 非专利名称 剂型 给药途径 规格/剂量 产品形式 批准日期 申请人 市场状态 许可证状态 参考产品非专利名称 参考产品专利名称
Roctavian 125720 001 351(a) valoctocogene roxaparvovec-rvox Injection Intravenous 16X 10E13GENOMES PER ML Single-Dose Vial 2023/06/29 Biomarin Pharmaceutical Inc. Rx Licensed
Lantidra 125734 001 351(a) donislecel-jujn Suspension Intravenous 1X10E6EQUIVALENT ISLET NUMBER (EIN) Bag 2023/06/28 CellTrans Inc. Rx Licensed
Ngenla 761184 001 351(a) somatrogon-ghla Injection Subcutaneous 24MG/1.2ML (20MG/ML) Autoinjector 2023/06/27 Pfizer Ireland Pharmaceuticals Unlimited Company Rx Licensed
Ngenla 761184 002 351(a) somatrogon-ghla Injection Subcutaneous 60MG/1.2ML (50MG/ML) Autoinjector 2023/06/27 Pfizer Ireland Pharmaceuticals Unlimited Company Rx Licensed
Rystiggo 761286 001 351(a) rozanolixizumab-noli Injection Subcutaneous 280MG/2ML (140MG/ML) Single-Dose Vial 2023/06/26 UCB, Inc. Rx Licensed
ELEVIDYS 125781 001 351(a) delandistrogene moxeparvovec-rokl Suspension Intravenous 1.33 10E14 vector genomes (vg)/kg/bodyweight(bw) Single-Dose Vial 2023/06/22 Sarepta Therapeutics, Inc. Rx Licensed
Fiasp 208751 004 351(a) insulin aspart Injection Subcutaneous 160UNITS/1.6ML (100UNITS/ML) Multi-Dose Cartridge 2023/06/21 Novo Nordisk Inc. Rx Licensed
Vyvgart Hytrulo 761304 001 351(a) efgartigimod alfa and hyaluronidase-qvfc Injection Subcutaneous 1,008MG/5.6ML; 11,200UNITS/5.6ML (180MG/2,000UNITS/ML) Single-Dose Vial 2023/06/20 Argenx BV Rx Licensed
Columvi 761309 001 351(a) glofitamab-gxbm Injection Intravenous 2.5MG/2.5ML (1MG/ML) Single-Dose Vial 2023/06/15 Genentech, Inc. Rx Licensed
Columvi 761309 002 351(a) glofitamab-gxbm Injection Intravenous 10MG/10ML (1MG/ML) Single-Dose Vial 2023/06/15 Genentech, Inc. Rx Licensed
Gamifant 761107 004 351(a) emapalumab-lzsg Injection Intravenous 50MG/2ML (25MG/ML) Single-Dose Vial 2023/06/07 Swedish Orphan Biovitrum AB (publ) Rx Licensed
Gamifant 761107 005 351(a) emapalumab-lzsg Injection Intravenous 100MG/4ML (25MG/ML) Single-Dose Vial 2023/06/07 Swedish Orphan Biovitrum AB (publ) Rx Licensed
Gamifant 761107 006 351(a) emapalumab-lzsg Injection Intravenous 250MG/10ML (25MG/ML) Single-Dose Vial 2023/06/07 Swedish Orphan Biovitrum AB (publ) Rx Licensed
Abrysvo 125769 001 351(a) Respiratory Syncytial Virus Vaccine Injection Intramuscular 120UG Single-Dose Vial 2023/05/31 Pfizer Inc. Rx Licensed
Yuflyma 761219 001 351(k) Interchangeable adalimumab-aaty Injection Subcutaneous 40MG/0.4ML Autoinjector 2023/05/23 CELLTRION, Inc. Rx Licensed adalimumab Humira
Yuflyma 761219 002 351(k) Interchangeable adalimumab-aaty Injection Subcutaneous 40MG/0.4ML Pre-Filled Syringe 2023/05/23 CELLTRION, Inc. Rx Licensed adalimumab Humira
VYJUVEK 125774 001 351(a) beremagene geperpavec-svdt Gel Topical 5.0x10^9 PFU/mL Single-Dose Vial 2023/05/19 Krystal Biotech, Inc. Rx Licensed
Epkinly 761324 001 351(a) epcoritamab-bysp Injection Subcutaneous 4MG/0.8ML Single-Dose Vial 2023/05/19 Genmab US, Inc. Rx Licensed
Epkinly 761324 002 351(a) epcoritamab-bysp Injection Subcutaneous 48MG/0.8ML Single-Dose Vial 2023/05/19 Genmab US, Inc. Rx Licensed
Cyltezo 761058 004 351(k) Interchangeable adalimumab-adbm Injection Subcutaneous 40MG/0.8ML Autoinjector 2023/05/18 Boehringer Ingelheim Pharmaceuticals, Inc. Rx Licensed adalimumab Humira
当前数据更新日期:2026年06月14日,更多信息请点击此处查询美国FDA药品数据库

数据库说明:

©2006-2026 DrugFuture->U.S. FDA Purple Book